Upadacitinib Safety Similar to Other Jakinibs for RA
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
Oxford University to Study Adalimumab as Potential COVID-19 Treatment
U.S. & E.U. Differ on Filgotinib for RA
Biologics May Prevent Cardiovascular Events in RA Patients
Guselkumab Approved for PsA
- 1
- 2
- 3
- …
- 20
- Next Page »